Parkinson's news from FierceBiotech
NewsBayer dumps Titan drug on mid-stage failure
Titan Pharmaceuticals announced this morning that its Parkinson's drug Spheramine failed to hit primary and secondary endpoints in a Phase IIb trial for moderate to advanced Parkinson's disease. Read more...
FDA staffers say that Eisai sedative appears safe
FDA staffers say that an experimental sedative developed by Eisai appears to be safe, but wants outside experts to consider whether it's safe enough to be administered by workers untrained in Read more...
Eisai drug flunks Parkinson's trial
Eisai's has halted development of Perampanel (E2007) for Parkinson's after the drug failed a late-stage trial. Compared with placebo, E2007 didn't show a significant difference in the primary Read more...
Study finds big gaps in clinical trial process
A new report out says that the clinical trial process routinely ignores women, the elderly, minorities, the disabled and people living in rural America. And the practice of ignoring large groups is Read more...
Developers could face surge in clinical trial lawsuits
A surge in early-stage drug testing could well set the stage for a spike in lawsuits from patients who feel they've been hurt by the drugs they're volunteering to test, says a new report in The Wall Read more...
SPOTLIGHT: Merck partners with Addex
Addex Pharmaceuticals' approach to receptor modulation has been validated in a new deal with Read more...
ALSO NOTED: What to expect from Pfizer's new CFO; BrainStorm plans stem cell trials; Phoenix biotech plans San Diego move; and
> Newtown, PA-based CollaGenex says that it has reaped positive data from a mid-stage study of Col-118 for the treatment of erythema. Read more...
New tests planned after Parkinson's drug fails trial
Merck KGaA and its development partner, Newron, say that a late-stage study of their experimental therapy for Parkinson's failed to demonstrate any significant effect. But the two developers refuse Read more...
Press Release: Roche and Synosis Therapeutics Announce Partnership to Explore Potential of Five Compounds Targeting the CNSPress Release: Roche and Synosis Therapeutics Announce Partnership to Explore Potential of Five Compounds Targeting the CNS Read more...Schering-Plough licenses hepatitis B drugShares of Valeant Pharmaceuticals and Metabasis Technologies jumped late Wednesday after they announced that Schering-Plough had licensed the experimental pradefovir for chronic hepatitis B. Valeant licensed the drug from Metabasis six years ago. Both companies will earn an up-front payment along with a schedule of milestones. "Pradefovir has the potential to offer improved treatment options for patients with chronic hepatitis B, a serious blood-borne infection affecting some 400 … Read more... | Press ReleasesPRESS RELEASE: Merck Initiates a New Phase III Clinical Trial of Safinamide in Early Parkinson’s Disease Merck Initiates a New Phase III Clinical Trial of Safinamide in Early Parkinson’s Disease MOTION-Trial Will Evaluate Safety and Efficacy of Two Doses of Safinamide (50 and 100 mg once daily) as Read more... PRESS RELEASE: PET scans show gene therapy normalizes brain function in Parkinson's patients PET scans show gene therapy normalizes brain function in Parkinson's patients MANHASSET, NY - Brain scans used to track changes in a dozen patients who received an experimental gene therapy show Read more... |
Get more Parkinson's coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets